Ikaros (encoded by Ikzf1) is the 'founding member' of a small family of transcription factors characterized by a central DNA-binding domain consisting of four zinc fingers (F1-F4) and a carboxy (C)-terminal dimerization region containing two additional zinc fingers (F5 and F6) 1 . Although Ikaros is broadly expressed in hematopoietic progenitors and their lineages, it functions mainly as key regulator of lymphopoiesis 1 . Ikaros-null (Ikzf1 −/− ) mice that lack the C-terminal zinc fingers fail to generate B lymphocytes, natural killer cells and fetal T cells but give rise to postnatal development of aberrant T cells 2 . In humans, heterozygous IKZF1 mutations are frequently associated with precursor B cell acute lymphoblastic leukemia (B-ALL) carrying the BCR-ABL1 translocation 3 . Although IKZF1 mutations in B-ALL correlate with poor prognosis 4 , little is yet known about the role of Ikaros in B-ALL and the development of B cells.
Ikaros is essential for the priming of lymphoid gene expression in multipotent progenitors (MPPs) 5 . In the absence of Ikaros, MPPs are unable to differentiate into common lymphoid progenitors (CLPs), which results in stringent arrest before B cell commitment in Ikzf1 −/− mice 6 . However, B cells are generated in Ikzf1 L/L mice, which carry a hypomorphic Ikzf1 mutation, although B cell differentiation is severely impaired at all developmental stages 7 . Notably, the Ikaros DNA-binding zinc fingers F1 and F4 affect B cell development differently, as deletion of F1 in mice leads to a much lower abundance of pre-B cells and subsequent B lymphopoiesis, in contrast to the more mildly altered B cell phenotype of mice with deletion of F4 (ref. 8) .
Productive variable heavy-chain region-to-diversity-joining heavy-chain region (V H -DJ H ) recombination of the immunoglobulin heavy-chain locus (Igh) in pro-B cells leads to expression of the immunoglobulin µ-chain, which forms the pre-B cell signaling complex (pre-BCR) together with the surrogate light chains λ5 (CD179b) and VpreB (CD179a) and the signal-transducing immunoglobulinassociated α-chain (CD79a) and immunoglobulin-associated β-chain (CD79b) 9 . Signaling via the pre-BCR in large pre-B cells leads to cessation of Igh recombination, proliferative expansion and subsequent differentiation into small pre-B cells that undergo rearrangement of genes encoding immunoglobulin light chains 9 . Signaling via the pre-BCR also induces expression of the Ikaros family member Aiolos 10 . Overexpression of Ikaros and Aiolos in cultured B-ALL and pre-B cell lines has linked the two transcription factors to the termination of pre-BCR signaling and control of exit from the cell cycle [10] [11] [12] [13] [14] . In those in vitro experimental settings, Ikaros and Aiolos silenced the expression of λ5 and VpreB 10, 11 and downregulated expression of the cell-cycle regulators c-Myc and cyclin D3 (refs. 12,14) . Although those findings have been confirmed and extended by a study of Ikaros binding and overexpression in a pre-B cell line 15 , the in vivo function of Ikaros in early B cell development has remained unknown in the absence of a conditional loss-of-function analysis. Here we studied the role of Ikaros in early B cell development by conditional mutagenesis and defined the molecular function of Ikaros by identifying regulated Ikaros target genes through genome-wide sequencing approaches. Our studies demonstrated that Ikaros stringently controlled the transition from pro-B cell to pre-B cell by promoting pre-BCR signaling and cell migration while suppressing cell adhesion.
RESULTS

Ikaros expression throughout B cell development
To investigate the function of Ikaros in B cell development, we created two altered Ikzf1 alleles. We generated the 'Ikzf1 ihCd2 allele' by inserting sequence encoding a biotin acceptor peptide at the final Ikzf1 codon and a reporter gene encoding the human cell-surface protein CD2 (lacking the intracellular domain) linked to an internal ribosomal entry site (ihCD2) upstream of the 3′ untranslated region of Ikzf1 (Supplementary Fig. 1a,b) . Notably, the Escherichia coli biotin ligase BirA (expressed from the ubiquitously expressed Rosa26 locus (Rosa26 BirA allele)) efficiently biotinylated Ikaros with the C-terminal biotin acceptor in Ikzf1 ihCd2/+ Rosa26 BirA/BirA pro-B cells (Supplementary Fig. 1a,c) and thus facilitated streptavidin-mediated precipitation of biotinylated Ikaros. Moreover, the development of B cells and T cells was similar in Ikzf1 ihCd2/ihCd2 Rosa26 BirA/BirA mice and their Ikzf1 ihCd2/+ Rosa26 BirA/BirA control littermates (Supplementary Fig. 1d ). Flow cytometry of cells from Ikzf1 ihCd2/+ mice demonstrated high expression of Ikzf1 in hematopoietic progenitor cells (MPPs, lymphoid-primed multipotent progenitors and CLPs) and throughout B cell development, from pro-B cells to terminally differentiated plasma cells, as well as during T lymphopoiesis, from the earliest thymic T cell progenitors (doublenegative (CD4 − CD8 − ) stage 1) to peripheral T cells, in contrast to its lower expression in erythroblasts, granulocytes and macrophages ( Fig. 1a and Supplementary Fig. 1e) . Notably, intracellular staining of Ikaros revealed an expression pattern for endogenous Ikaros protein ( Supplementary Fig. 1f,g ) that was similar to that of Ikzf1 mRNA (detected by expression of human CD2; Fig. 1a) during B cell development. These data indicated that the expression of Ikaros was not post-transcriptionally regulated in B cells.
Impaired pro-B cell-to-pre-B cell transition after loss of Ikaros
For functional studies, we generated a second, loxP-flanked Ikzf1 allele (Ikzf1 fl ) by inserting loxP sites flanking exon 8 ( Supplementary  Fig. 2a-c) , which encodes the two C-terminal zinc fingers responsible for Ikaros dimerization 16 . Lymphocyte development was normal in homozygous Ikzf1 fl/fl mice as well as in Ikzf1 fl/− mice with one Ikzf1-null allele (Ikzf1 − ) 2 (Supplementary Fig. 2d,e) . As a mouse line expressing Cre recombinase from the gene encoding CD79a (Cd79a-Cre; also known as mb1-Cre) 17 initiates deletion of loxP-flanked genes at the transition from pre-pro-B cell to committed pro-B cell 18 , we used this mouse line for deletion of the loxP-flanked Ikzf1 allele in B cells of Ikzf1 fl/+ control mice and their Ikzf1 fl/− littermates. Notably, B cell-specific deletion of Ikzf1 did not lead to B cell leukemia in Cd79a-Cre Ikzf1 fl/− mice during a 1-year observation period, in contrast to the development of T cell leukemia in all Rag2-Cre Ikzf1 fl/− mice (with Cre expressed from recombination-activating gene 2) and Il7r-Cre Ikzf1 fl/− mice (with Cre expressed from the gene encoding the receptor for interleukin 7 (IL-7)) due to deletion of Ikzf1 in the T cell lineage (Supplementary Fig. 2f ). Flow cytometry of the bone marrow revealed that Cd79a-Cre Ikzf1 fl/− mice had sixfold fewer total B cells than their Cd79a-Cre Ikzf1 fl/+ control littermates had, due to an almost complete loss of pre-B cells and all subsequent developmental stages of B cells (Fig. 1b,c) . In contrast, the bone marrow of Cd79a-Cre Ikzf1 fl/− mice had twofold more c-Kit hi pro-B cells (c-Kit hi CD19 + CD2 − IgM − IgD − ) than that of their control littermates (Fig. 1b,c) , consistent with the finding that Ikzf1 was efficiently deleted in those pro-B cells (Fig. 1d) . In addition to containing c-Kit hi pro-B cells, the bone marrow of Cd79a-Cre Ikzf1 fl/− mice contained a second prominent population of c-Kit lo cells (c-Kit lo CD19 + CD2 − IgM − IgD − ) (Fig. 1b,e) . With progressing age, the number of those c-Kit lo cells (Fig. 1e) . Together these data identified an essential role for Ikaros in controlling the transition from pro-B cell to pre-B cell.
Proliferation defect of Ikaros-mutant pro-B cells
Cell-cycle analysis revealed that c-Kit hi pro-B cells (CD19 + B220 + CD2 − IgM − IgD − ) proliferated equally well in the bone marrow of Cd79a-Cre Ikzf1 fl/− and their Cd79a-Cre Ikzf1 fl/+ control littermates (Fig. 2a,b) . In contrast, c-Kit lo cells (CD19 + B220 + CD2 − IgM − IgD − ) of Cd79a-Cre Ikzf1 fl/− mice 'preferentially' accumulated in the G1-G0 phases of the cell cycle, in contrast to the large cycling c-Kit lo pre-B cells (CD19 + B220 + CD2 − IgM − IgD − ) of Cd79a-Cre Ikzf1 fl/+ control mice (Fig. 2a,b) . Notably, the arrest in G1 did not result in apoptosis, as it did not lead to an increase in c-Kit lo cells in the sub-G1 cell fraction (Fig. 2a,b) . Consistent with those findings, c-Kit lo cells in Cd79a-Cre Ikzf1 fl/− mice were small, in contrast to the large cycling c-Kit lo pre-B cells of their Cd79a-Cre Ikzf1 fl/+ control littermates (Fig. 2c) . Unexpectedly, all c-Kit lo cells in Cd79a-Cre Ikzf1 fl/− mice expressed a functionally rearranged immunoglobulin µ-chain similar to that of the large c-Kit lo pre-B cells in Cd79a-Cre Ikzf1 fl/+ control mice (Fig. 2c) . However, expression of the surrogate light chains λ5 and VpreB was not downregulated in Cd79a-Cre Ikzf1 fl/− c-Kit lo cells, in contrast to their expression in the large c-Kit lo and small CD2 + pre-B cells of Cd79a-Cre Ikzf1 fl/+ mice (Fig. 2c) ; this suggested that pre-BCR signaling was defective despite the expression of all pre-BCR components, including the signaling chains CD79a and CD79b (discussed below). As the c-Kit lo cells from Cd79a-Cre Ikzf1 fl/− mice in the absence of pre-BCR signaling did not have pre-B cell-specific features other than expression of immunoglobulin µ-chain, we call these cells as aberrant c-Kit lo 'pro-B cells' here. Notably, we were able to propagate Cd79a-Cre Ikzf1 fl/− pro-B cells in vitro in the presence of IL-7 and OP9 stromal cells, as they had only a minor cell-cycle defect under these pro-B cell culture conditions ( Supplementary Fig. 3a-e) .
Half of the c-Kit hi pro-B cells in Cd79a-Cre Ikzf1 fl/− mice expressed immunoglobulin µ-chain, compared with only 15% of the c-Kit hi pro-B cells from their Cd79a-Cre Ikzf1 fl/+ control littermates (Fig. 2c) ; this suggested that µ-chain expression provided a survival advantage in vivo in the absence of Ikaros. To test that idea, we analyzed the effect of Ikzf1 deletion on a background deficient in the recombinase RAG-2, which prevents variable-(diversity)-joining (V(D)J) recombination at the Igh locus 19 . Indeed, the bone marrow of Cd79a-Cre Ikzf1 fl/− Rag2 −/− mice had threefold fewer pro-B cells than that of their Cd79a-Cre Ikzf1 fl/+ Rag2 −/− control littermates, due to a 'preferential' loss of c-Kit int pro-B cells (Supplementary Fig. 3f-h) . Collectively, these data demonstrated that pro-B cell-specific deletion of Ikzf1 arrested development at an aberrant µ-chain + c-Kit lo 'pro-B cell' stage due to a pre-BCR signaling defect.
Identification of regulated Ikaros target genes
To determine the genome-wide binding pattern of Ikaros, we obtained pro-B cells from the bone marrow of Ikzf1 ihCd2/ihCd2 Rosa26 BirA/BirA Rag2 −/− mice and cultured these cells short-term, and also enriched CD4 + CD8 + double-positive (DP) thymocytes from Ikzf1 ihCd2/ihCd2 Rosa26 BirA/BirA mice by immunomagnetic selection, and assessed these cells by streptavidin-mediated chromatin precipitation coupled with deep sequencing (Bio-ChIP-Seq) 20 . Bio-ChIP-Seq analysis identified genes with unique Ikaros peaks in pro-B cells (Nkd2) or DP thymocytes (Syt13), as well as common Ikaros-binding sites in both cell types (Malt1; Fig. 3a,b) . 'Peak calling' with a stringent P value of < 10 −10 identified 9,878 and 7,740 Ikaros-binding regions (Fig. 3b) , which defined 8,391 and 4,989 Ikaros target genes in pro-B cells and DP T cells, respectively, with an overlap of 3,633 genes (Fig. 3c) . By analyzing the sequences at Ikaros peaks with de novo motif-discovery programs, we identified similar Ikaros-binding motifs in pro-B cells and DP T cells (Fig. 3d) , which resembled published Ikaros consensus recognition sequences 21, 22 . Those Ikaros-binding motifs were present at a high frequency in common and unique Ikaros peaks of both cell types (Fig. 3d) , which confirmed the specificity of Ikaros binding at the peaks identified by Bio-ChIP-Seq analysis.
To identify regulated Ikaros target genes, we analyzed Ikarosdeficient and control pro-B cells by high-throughput RNA sequencing (RNA-Seq). For this, we isolated c-Kit hi pro-B cells from the bone marrow of Cd79a-Cre Ikzf1 fl/− and Cd79a-Cre Ikzf1 fl/+ mice by flow cytometry (Supplementary Fig. 4a ) or cultured the respective Fig. 3a) . We refer to the Cd79a-Cre Ikzf1 fl/− and Cd79a-Cre Ikzf1 fl/+ pro-B cells as 'Ikzf1 ∆/− ' and 'Ikzf1 ∆/+ ' pro-B cells, respectively, as the loxP-flanked Ikzf1 allele was completely deleted in both cell types ( Fig. 1d and Supplementary Fig. 3b ). RNA-Seq analysis detected only Ikzf1 transcripts from which exon 8 was deleted in cultured Ikzf1 ∆/− pro-B cells, in contrast to the presence of small amounts of mRNA containing exon 8 in Ikzf1 ∆/+ pro-B cells sorted ex vivo (Supplementary Fig. 4b,c) . Consequently, cultured Ikzf1 ∆/− pro-B cells had a much lower abundance of RNA transcripts from the activated Ikaros target Cplx2 than did Ikzf1 ∆/− pro-B cells sorted ex vivo (Fig. 3e) . We identified Ramp1 as a repressed target of Ikaros, as its expression was induced in Ikzf1 ∆/− pro-B cells cultured in vitro or sorted ex vivo (Fig. 3e) . As Ikaros-regulated genes were affected more in cultured Ikzf1 ∆/− pro-B cells because of their complete lack of Ikaros protein ( Supplementary Fig. 3c Expression (RPM) Ikzf1 
Function of proteins encoded by Ikaros target genes
The 131 activated and 180 repressed Ikaros target genes encoded proteins of distinct functional classes ( Fig. 4a and Supplementary Table 1) . Notably, the largest functional class for activated Ikaros targets and repressed Ikaros targets included 31 (24%) and 39 (22%) signal transducers, respectively ( Fig. 4a) , which indicated an important role for Ikaros in controlling intracellular signaling. Notably, the second largest functional class consisted of 19 activated genes and 18 repressed genes encoding cell surface receptors (Fig. 4a) . By flow cytometry analysis of Ikzf1 ∆/− and Ikzf1 ∆/+ pro-B cells, we verified the activation of Icam1 and Bst1, as well as the repression of Cd22 and Cd72, at the protein level (Fig. 4b) . Moreover, 13 activated Ikaros targets and 19 repressed Ikaros targets encoded transcriptional regulators ( Fig. 4a) , which may be responsible for the indirect effects of Ikaros-mediated gene control. One of the repressed targets, Ikzf3, encodes the transcription factor Aiolos, the most closely related family member of Ikaros 23 . Ikzf3 expression was derepressed in c-Kit hi pro-B cells obtained from Cd79a-Cre Ikzf1 fl/− mice and cultured in vitro or sorted ex vivo ( Supplementary Fig. 4d,e) . Single-cell analysis of intracellular Aiolos staining revealed that a large proportion of Ikzf1 ∆/− pro-B cells, either cultured in vitro or sorted ex vivo, expressed Aiolos protein to the same extent that small pre-B cells from Cd79a-Cre Ikzf1 fl/+ mice did (Fig. 4c) . Hence, Aiolos was unable to compensate for the loss of Ikaros in early B cell development, which indicated that Aiolos and Ikaros had nonredundant functions despite their high sequence similarity.
Ikaros controls different pre-BCR signaling pathways Consistent with control of the transition from pro-B cell to pre-B cell by Ikaros, several Ikaros-activated genes encoded positive regulators of signaling via the pre-BCR or BCR, such as a costimulatory receptor (Slamf6), adaptors (Lcp2 (which encodes SLP-76), Lat and Grap2), kinases (Blk and Pik3r5 (which encodes a subunit of phosphatidylinositol-3-OH kinase (PI(3)K))) and the phosphatase calcineurin (Ppp3cc (which encodes a subunit of calcineurin)) ( Fig. 4a and Supplementary Fig. 5a ). Moreover, Ikaros repressed genes encoding negative regulators of signaling via the pre-BCR or npg BCR, including inhibitory receptors (Cd22, Cd72, Fcgr2b (which encodes FcγRIIb), Pdcd1 (which encodes PD-1)) and phosphatases (Ptpn6 (which encodes SHP-1) and Inppl1 (which encodes SHIP-2)) (Fig. 4a,b and Supplementary Fig. 5a ). Hence, deregulation of those Ikaros targets in Ikaros-deficient pro-B cells could explain the observed block in B cell development. To directly investigate intracellular signaling downstream of the pre-BCR, we took advantage of immunoglobulin µ-chain-negative Rag2 −/− pro-B cells, which express the signaling chains CD79a and CD79b in a complex with calnexin on their cell surface 24 . Crosslinkage of that complex with antibody HM79 to CD79b mimics pre-BCR signaling and leads to pre-B cell development in vivo 24 . Stimulation with that antibody to CD79b efficiently induced intracellular calcium mobilization in Cd79a-Cre Ikzf1 fl/+ Rag2 −/− control pro-B cells, in contrast to stimulation with an isotype-matched control antibody to the γδ T cell antigen receptor (TCRγδ) (Fig. 5a) . However, we did not observe intracellular calcium signaling in Cd79a-Cre Ikzf1 fl/− Rag2 −/− pro-B cells in which CD79b was crosslinked (Fig. 5a) . Moreover, the antibody to CD79b was unable to induce phosphorylation of the kinase Akt at Ser473 in response to activation of PI(3)K in Cd79a-Cre Ikzf1 fl/− Rag2 −/− pro-B cells, although it increased the abundance of Akt phosphorylated at Ser473 in Cd79a-Cre Ikzf1 fl/+ Rag2 −/− control pro-B cells (Fig. 5b) . Likewise, we did not observe phosphorylation of the mitogenactivated protein kinase (MAPK) Erk1/2 at Thr202 and Tyr204 in the absence of Ikaros (Fig. 5b) . Together these data revealed an important role for Ikaros in activating the downstream PI(3)K, MAPK and calcium signaling pathways of the pre-BCR.
Ikaros regulates the adhesion and migration of cells Ikaros activated genes encoding adhesion and chemokine receptors (Icam1 (which encodes CD54), Bst1 (which encodes CD157) and Cxcr5), a Ras effector (Rassf5) and an adaptor (Grb7) that have been linked to the adhesion and migration of cells (Fig. 4a,b and Supplementary Fig. 5b ). However, Ikaros mainly repressed genes encoding adhesion molecules (Cdh22, Itga9, Plxnb2, Cd82), a chemokine receptor (Ccr2), kinases (Wnk2, Pkn3 and Ptk2 (which encodes FAK1)), an adaptor (Jub), a GTPase (Rhoq) and seven guanine nucleotide-exchange factors (Tiam2, Bcar3, Dock1, Dock6, Trio, Fgd1 and Swap70) that induce signaling of the small GTPases Cdc42, Rac and Rho, leading to actin polymerization and cytoskeletal rearrangements ( Fig. 4a and Supplementary Fig. 5b ). These findings suggested that Ikaros controlled the migration and adhesion of pro-B cells. In a Transwell migration assay, Cd79a-Cre Ikzf1 fl/− Rag2 −/− pro-B cells were unable to migrate toward a source of the chemokine CXCL12 (SDF-1α), in contrast to Cd79a-Cre Ikzf1 fl/+ Rag2 −/− control pro-B cells (Fig. 5c) , although Cxcr4 (which encodes the receptor for CXCL12) had similar expression in both cell types (data not shown). In contrast, in the presence of CXCL12, the Cd79a-Cre Ikzf1 fl/− Rag2 −/− pro-B cells were sixfold more adherent than were Cd79a-Cre Ikzf1 fl/+ Rag2 −/− control pro-B cells to a surface coated with VCAM-1 (Fig. 5d) , the ligand for the integrin VLA-4 (α 4 β 1 ; encoded by Itga4 and Itgb1), which had similar expression in the two pro-B cell types (data not shown). Hence, Ikaros promoted the migration of pro-B cells and simultaneously prevented cell adhesion in early B lymphopoiesis.
Ikaros binds to active promoters and enhancers
To gain mechanistic insight into the Ikaros-mediated regulation of genes, we next investigated how Ikaros interacted with the regulatory 'landscape' of Rag2 −/− pro-B cells 20 already assessed by genome-wide mapping of DNase I-hypersensitive (DHS) sites and active transcription start sites (TSSs; identified by the CAGE ('cap analysis of gene expression') method 25 ). We found that over half of all Ikaros-binding sites (54%; 5,348) were located at active promoters defined by the presence of active TSSs (CAGE 'reads') ( Fig. 6a) . Moreover, one third of all Ikaros peaks (30%; 2,932) mapped to distal elements, characterized by the presence of a DHS site in the absence of an active TSS (no significant CAGE 'reads') or annotated TSS. The subcategorization of distal elements into active enhancers as well as poised, inactive and repressed distal elements by genome-wide mapping of active histone marks (dimethylation of histone H3 at Lys4 (H3K4me2), trimethylation of histone H3 at Lys4 (H3K4me3) and acetylation of histone H3 at Lys9 (H3K9ac)) and repressive histone marks (trimethylation of histone H3 at Lys27 (H3K27me3)) 20 revealed that 71% (2,073) of all Ikarosbound distal elements corresponded to active enhancers (Fig. 6a) . npg Moreover, by including all regulatory elements of the pro-B cell genome, we demonstrated that Ikaros bound to 60% of all active promoters but only 12% of all inactive promoters (Fig. 6b) . The binding of Ikaros showed further enrichment at active enhancers (30%) relative to its binding at all distal elements (12%) (Fig. 6b) . We therefore concluded that Ikaros 'preferentially' bound to active promoters and enhancers in pro-B cells.
As de novo motif-discovery analysis of Ikaros-binding regions did not identify a recognition sequence for a transcription factor other than Ikaros, we determined the colocalization of Ikaros peaks with binding sites of the transcription factors Pax5, EBF1, PU.1 and IRF4 in pro-B cells by multiple overlap analysis of the corresponding ChIP-Seq data 20, 26 (examples of such binding sites, Supplementary Fig. 6a ). There was a high co-occurrence of binding sites for IRF4 (73%) and PU.1 (54%) at all Ikaros peaks (9,878) (Fig. 6c) . We noted a similar frequency of colocalization for IRF4-and PU.1-binding sites at Ikaros peaks for activated Ikaros targets, whereas we observed less co-occurrence at repressed Ikaros targets (Fig. 6c) , which resulted in a greater abundance of Ikaros-only peaks. In contrast, binding sites for the B cell-commitment factors EBF1 and Pax5 were present at a lower frequency at all Ikaros peaks but showed enrichment at Ikaros peaks present at regulated Ikaros target genes, with the strongest effect seen for activated Ikaros target genes (Fig. 6d) . As regulated Pax5 target genes have been identified in pro-B cells 20 , we determined how many of the activated and repressed Ikaros targets with co-occurrence of Ikaros-and Pax5-binding sites were also dependent on Pax5 for their expression in pro-B cells. Notably, Pax5 regulated 25% and 28% of those activated (99) and repressed (100) Ikaros targets, respectively ( Supplementary  Fig. 6b ), which represented a substantial enrichment compared with the 1.5% activated and 3% repressed Pax5 targets identified among all Pax5-bound genes in pro-B cells 20 . These data therefore suggested that Ikaros acted together with Pax5 to regulate some of its target genes.
Chromatin changes at regulated Ikaros targets
To investigate how Ikaros influences the chromatin state at promoters and enhancers of its target genes, we mapped, by ChIP-Seq, the active histone marks H3K4me3 and H3K9ac in Cd79a-Cre Ikzf1 fl/− Rag2 −/− and Cd79a-Cre Ikzf1 fl/+ Rag2 −/− pro-B cells cultured short-term. For analysis of these ChIP-Seq data, we classified all genes according to their degree of Ikaros-dependent regulation and the presence or absence of Ikaros-binding sites at their regulatory elements. The loss of Ikaros led to a greater abundance of the active histone marks H3K4me3 and H3K9ac at promoters and distal elements of the most strongly repressed Ikaros targets (with a difference in gene expression over fivefold), whereas it resulted in significantly fewer of those histone modifications at promoters and enhancer of highly activated Ikaros targets (with a difference in gene expression over fivefold) (Fig. 7) . Notably, genes indirectly regulated by Ikaros were characterized by a considerably lower density of H3K4me3 and H3K9ac at their promoter and distal elements that lacked Ikaros binding (Fig. 7) , although these genes had expression similar to that of the regulated Ikaros targets (data not shown). Together these data indicated a role for Ikaros in the induction or suppression of active chromatin at activated and repressed target genes, respectively.
As Ikaros has been linked to chromatin regulation through its interaction with the nucleosome-remodeling and histone-deacetylase (NuRD) complex 27 (Fig. 3b) and Ikaros-binding sites present at activated and repressed Ikaros target genes (Fig. 3f,g ). Numbers in bars indicate the frequency of peaks for various combinations of transcription factors (right margin); numbers above bars indicate total peaks. Supplementary Figure 6a shows examples of genes with overlapping transcription factor-binding sites. Data are representative of one experiment.
npg
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The 6,611 Mi-2β peaks identified at promoters in Ikzf1 ∆/+ control pro-B cells revealed a substantial overlap with Ikaros peaks (71%) and a strong correlation between the binding density of the two transcriptional regulators at promoters (Supplementary Fig. 7a,b) , consistent with the idea that Ikaros can recruit the NuRD complex to its binding sites 22, 27 . In contrast, there was little correlation between the binding of Mi-2β and that of Ikaros at distal elements in pro-B cells, as Ikaros bound to only 26% (11,987) of all Mi-2β peaks at these elements ( Supplementary Fig. 7a,b) . Notably, the binding of Mi-2β was similar in Ikaros-deficient (Ikzf1 ∆/− ) pro-B cells and control (Ikzf1 ∆/+ ) pro-B cells (Supplementary Fig. 7b,c) , which suggested that Ikaros was not required for retention of the NuRD complex at its binding sites. Moreover, loss of Ikaros did not affect the abundance of H3K9ac at Mi-2β-or Ikaros-binding sites in pro-B cells ( Supplementary  Fig. 7b,c) , in contrast to the observed global decrease of H3K9 acetylation at the corresponding sites in Ikzf1 −/− thymocytes 22 . Together our data did not support the proposal of a role for the NuRD complex in controlling the chromatin changes observed at promoters and distal elements of the regulated Ikaros targets in early B cell development.
Ikaros regulates distinct genes in early B lymphopoiesis
As Ikaros had similar expression in lymphoid progenitor cells, pro-B cells and pre-B cells (Fig. 1a) , we investigated by RNA-Seq analysis how the regulated Ikaros targets identified in pro-B cells (Fig. 3f,g ) were expressed during the transition from B cell-biased lymphoid progenitor (BLP; a subpopulation of CLPs) to small pre-B cell. The Ikaros targets Pld4, Cenpv and Emid1 were repressed in pro-B cells but were expressed in BLPs and pre-B cells (Fig. 8a) . We also noted a similar trend for repressed Ikaros targets encoding molecules involved in cell migration and adhesion (Supplementary Fig. 8a) . Conversely, the targets Nkd2, Alpl and Smtnl2 were activated in pro-B cells but repressed in BLPs and pre-B cells (Fig. 8a) . To determine whether those findings could be generalized, we analyzed the expression of all activated and repressed Ikaros target genes (identified in pro-B cells) in scatter plots displaying the difference in gene expression in BLPs versus pro-B cells and in pro-B versus pre-B cells (Fig. 8b) . Moreover, we plotted the change in expression of the regulated Ikaros targets for each cell pair as a density diagram (Fig. 8c) . As shown by these analyses, most repressed Ikaros targets in pro-B cells were upregulated in BLPs and pre-B cells, whereas most activated Ikaros targets had high expression only in pro-B cells. These data therefore suggested that Ikaros targets were regulated differently at the onset of B cell development. As the dynamic regulation of Ikaros targets may have reflected differences in the binding of Ikaros during early B lymphopoiesis, we investigated by Bio-ChIP-Seq the Ikaros-binding patterns of cultured Ikzf1 ihCd2/ihCd2 Rosa26 BirA/+ progenitor cells in which loxP-flanked alleles encoding EBF1 (Ebf1 fl/fl ) were deleted by Cre expressed from the hematopoietic compartment-specific Vav1 promoter (Vav-Cre Ebf1 fl/fl (Ebf1 ∆/∆ )); these cells are arrested by the loss of EBF1 at a developmental stage similar to that of BLPs 26 . Comparison of the Ikaros-binding patterns of Ebf1 ∆/∆ progenitor cells and Rag2 −/− pro-B cells revealed common Ikaros peaks, although more than half of all Ikaros peaks showed 'preferential' Ikaros binding in only one of the cell types (Fig. 8d) . To identify regulated Ikaros targets in uncommitted lymphoid progenitor cells, we used a tetracyclineinducible expression system for short hairpin RNA (shRNA) 29 with the improved 'miR-E' backbone 30 to downregulate Ikaros function in Ebf1 −/− progenitor cells. We infected those progenitor cells with the TRMPVIR retrovirus 29 , which encodes either an Ikzf1-specific shRNA (Ik4056 or Ik2709) or a control shRNA (Ren713) that targets renilla luciferase (Supplementary Fig. 8b-e) 
Ikzf1
∆/+ Rag2 Fig. 8e,f) . Ikaros bound to a subset of those regulated genes in Ebf1 ∆/∆ progenitor cells (Fig. 8f) . Notably, most of the regulated Ikaros targets, which we had identified in pro-B cells (Fig. 3f,g ) and further linked to pre-BCR signaling or cell migration and adhesion (Supplementary Fig. 5a,b) , were not regulated by Ikaros in Ebf1 −/− progenitor cells (Fig. 8g,h ). Together these data demonstrated that Ikaros bound to and regulated distinct target genes at different stages of early B cell development.
DISCUSSION
Ikaros is an essential regulator of early B cell development 2, 6, 7 .
Here we have demonstrated that the loss of Ikaros in pro-B cells arrested B cell development at a small aberrant c-Kit lo 'pro-B cell' stage due to a defect in pre-BCR signaling. Through ChIP-Seq and RNA-Seq approaches, we identified a plethora of activated and repressed Ikaros targets, which provided insight into the molecular function of Ikaros in early B lymphopoiesis.
The expression of Aiolos, a closely related member of the Ikaros family 23 , is activated upon pre-BCR signaling 10 . In contrast to the loss of Ikaros, Aiolos deficiency results in a twofold increase in large and small pre-B cells in Aiolos-deficient (Ikzf3 −/− ) mice 31, 32 . Here, we identified Ikzf3 as a repressed Ikaros target, which suggests that its Ikaros-mediated repression must be antagonized by pre-BCR signaling, possibly through the combined action of IRF4 and IRF8 (ref. 11) or post-translational modifications 33 . However, derepression of Aiolos did not compensate for the loss of Ikaros, as it failed to 'rescue' the developmental block of Ikaros-deficient pro-B cells. Hence, Aiolos and Ikaros must have nonredundant functions in pre-BCR signaling, at least in the regulation of a subset of their target genes.
Although Ikaros had similar expression throughout early B cell development, its activated and repressed target genes identified in pro-B cells were regulated differently earlier in lymphoid progenitor cells (BLPs; Ebf1 −/− progenitor cells) and later in small pre-B cells. 
npg
A r t i c l e s
That dynamic expression pattern could be explained by the observed stage-specific binding of Ikaros, as well as by the cooperation of Ikaros with different transcription factors at its target genes. The last point is best exemplified by the B lineage-commitment factor Pax5, which is absent from lymphoid progenitors but is expressed in pro-B cells 34 , in which its binding showed enrichment at Ikaros peaks of activated Ikaros targets. The observed minimal overlap of Ikaros-regulated genes in lymphoid progenitor cells and pro-B cells provided further evidence that Ikaros regulates its targets in a stage-specific manner, similar to the action of Pax5 and EBF1 in early and late development of B cells 20, 26 . The block at the transition from pro-B cell to pre-B cell in Cd79a-Cre Ikzf1 fl/− mice was caused by a defect of pre-BCR signaling. Although Ikaros-deficient pro-B cells expressed all components of the pre-BCR, they were unable to activate the PI(3)K, MAPK and calcium signaling pathways upon stimulation of the pre-BCR. That phenotype was explained by the dual role of Ikaros in activating genes encoding positive regulators of those downstream signaling pathways, including adaptors (SLP-76, Lat and Grap2), kinases (PI(3)K subunits and BLK) and calcineurin (Ppp3cc), while simultaneously repressing genes encoding negative regulators of pre-BCR signaling, such as inhibitory receptors (CD22, CD72, FcγRIIb and PD-1) and phosphatases (SHP-1 and SHIP-2). Notably, the greater abundance of those inhibitory receptors and their associated phosphatase SHP-1 (due to their higher expression) in Ikaros-deficient pro-B cells may interfere with signaling of all downstream pre-BCR pathways by antagonizing phosphorylation of the kinase Syk 9 .
The enhanced substrate adhesion and diminished migration of Ikaros-deficient pro-B cells identified a previously unknown function for Ikaros in early B cell development. Cells adhere to the extracellular matrix mainly through integrin-linked focal adhesion complexes that induce, in response to integrin clustering, signaling from the focal adhesion kinase FAK1 (Ptk2) to the small GTPases Rho, Rac and Cdc42, which leads to rearrangements of the actin cytoskeleton. Notably, Ikaros repressed seventeen genes encoding molecules with known functions in cell adhesion and migration, including FAK1, and seven genes encoding guanine nucleotide-exchange factors (Tiam2, Bcar3, Dock1, Dock6, Trio, Fgd1 and Swap70) that activate, with different specificities, the small GTPases Rho (Trio) 35 , Rac (Tiam2, Dock1 or Swap70) [36] [37] [38] and Cdc42 (Dock6, Fdg1 or Bcar3) [39] [40] [41] . The greater abundance of FAK1 and the seven guanine nucleotideexchange factors (due to their higher expression) probably contributed to the efficient substrate adhesion of Ikaros-deficient pro-B cells by enhancing the activity of multiple small GTPases. The adhesion and migration of cells are dynamically regulated during early B cell development, as uncommitted lymphoid progenitor cells adhere to CXCL12-expressing reticular cells and pro-B cells adhere to IL-7-expressing stromal cells, whereas pre-B cells migrate away from both bone marrow niches 42 . Notably, genes encoding molecules involved in adhesion and migration, which were repressed by Ikaros in pro-B cells, had high expression in BLPs and/or pre-B cells; this indicated that Ikaros contributed to the dynamic regulation of cell adhesion and migration during early B cell development.
We furthermore demonstrated a role for Ikaros in inducing active chromatin at promoters and enhancers of activated target genes and in chromatin silencing at regulatory elements of repressed target genes. Ikaros has been linked to chromatin regulation through its interaction with the NuRD complex 27, 28 . As a DNA-binding component, Ikaros tethers the Mi-2β-containing NuRD complex to the permissive chromatin of active genes in DP T cells 22 . Notably, Ikaros binding seems to negatively regulate the activity of the NuRD complex, as loss of Ikaros leads to a local increase in chromatin remodeling and histone deactylation 22 . Similar to T cells in which Ikzf1 is mutated 22 , the NuRD complex remained bound at Ikaros-binding sites in Ikarosdeficient pro-B cells. Analogous to the T cell situation 22 , increased NuRD activity in the absence of Ikaros could be responsible for the loss of H3K9ac at regulatory elements of activated Ikaros target genes but fails to explain the observed increase of H3K9ac at repressed target genes in Ikaros-deficient pro-B cells. In contrast to T cells in which Ikzf1 is mutated 22 , we did not observe a global decrease in acetylation of H3K9 at Mi-2β-and Ikaros-binding sites in Ikarosdeficient pro-B cells, which may indicate a different role for Ikaros in chromatin regulation during the early development of B cells and T cells. Alternatively, the discrepancy could be caused by the different deletion strategies used, as the H3K9ac pattern may never be properly established in the absence of Ikaros during the differentiation of hematopoietic stem cells into thymocytes in Ikzf1 −/− mice, whereas our conditional mutagenesis acutely inactivated Ikzf1 only at the pro-B cell stage. Notably, Ikaros also interacts with the corepressor CtBP 43 and Sin3 complexes that contain histone deacetylases 44 , both of which may be involved in chromatin silencing at repressed Ikaros targets. Such interpretations, however, are complicated by the fact that Aiolos not only interacts with the NuRD and Sin3 corepressor complexes as Ikaros does 44, 45 but is also expressed in pro-B cells in which Ikzf1 is mutated. The observed chromatin changes in Ikaros-deficient pro-B cells may therefore suggest that Ikaros and Aiolos also have some nonredundant functions in chromatin regulation.
Ikaros is a potent tumor suppressor in BCR-ABL1 + B-ALL 3 . Over half the IKZF1 mutations in B-ALL are heterozygous focal deletions that eliminate exons 4-7 and thus result in expression of the Ik6 dominant-negative isoform of Ikaros 3, 46 . Notably, homozygous deletion of the entire IKZF1 gene is observed in 11-14% of all B-ALL cases with IKZF1 mutations 3, 46 . Hence, the deregulation of gene expression identified after loss of Ikaros in our study here may also contribute to the formation of B-ALL, which is arrested at an early stage similar to the stage at which B cell development was arrested in Cd79a-Cre Ikzf1 fl/− mice. Unexpectedly, however, Cd79a-Cre Ikzf1 fl/− mice did not develop B cell leukemia despite accumulating an aberrant 'pro-B cell' population. Hence, similar to PAX5 mutations 47 , loss of Ikaros contributes to the development of B-ALL only in the presence of additional driver mutations, a topic for future studies.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Mice. The following mice were maintained on the C57BL/6 genetic background: Ikzf1 +/− mice 2 , Ebf1 +/− mice 48 Generation of the Ikzf1 ihCd2 allele. The targeting vector for generating the Ikzf1 ihCd2 allele was obtained by insertion of the following sequences, in the 5′-to-3′ direction (Supplementary Fig. 1a) , into the Ikzf1 bacterial artificial chromosome (BAC) bMQ-185J16 (129Sv) by recombination-mediated genetic engineering in E. coli: a 233-base pair (bp) MfeI-AscI fragment containing C-terminal tag sequences (fused in frame to the final Ikzf1 codon), a 1.8-kilobase (kb) AscI-SalI fragment containing the ihCd2 reporter gene (flanked by flippase-recognition target sites) and a 1.9-kb SalI-XhoI fragment containing the promoter of the mouse mouse gene encoding phosphoglycerate kinase (Pgk1) linked to the gene encoding neomycin resistance (neo r ) (flanked by loxP sites). The tag sequences contained cleavage sites for the PreScission and TEV proteases, epitopes for antibodies to the tags Flag and V5 and a biotin acceptor sequence (Biotin) for biotinylation by the E. coli biotin ligase BirA 54 . In a second step, the Ikzf1 ihCd2 targeting vector was generated by excision and insertion of the integrated sequences together with the flanking 5′ (5.0-kb) and 3′ (1.7-kb) homology regions by recombinationmediated genetic engineering from the modified BAC into the pBV-DTA-pA plasmid containing a gene encoding herpes simplex virus thimidine kinase (for negative selection). DNA (15 µg) linearized with SgrA1 was transfected by electroporation into cells (1 × 10 7 ) of the hybrid C57BL/6 × 129Sv ES cell line A9, followed by selection with 250 µg/ml of the aminoglycoside G418. PCR + clones were verified by Southern blot analysis before injection into C57BL/6 blastocysts and the generation of 'Ikzf1 ihCd2-Neo/+ ' mice. The Ikzf1 ihCd2 allele was obtained by crossing Ikzf1 ihCd2-Neo/+ mice with Mox2 Cre/+ mice 50 and was verified by Southern blot analysis of DNA obtained from tail tissue and digested with XbaI. The following primers were used for PCR genotyping of Ikzf1 hCd2/+ mice: 5′-GAGGAGTCGGAGAAATGATGAG-3′ (a), 5′-TCCACAGATACAGAGAGCAACG-3′ (b) and 5′-GGAGAGTGTT AGGAAGCCACAT-3′ (c). The Ikzf1 ihCd2 allele was identified as an 834-bp PCR fragment with the primer pair a and c, and the wild-type Ikzf1 allele was identified as a 645-bp PCR fragment with the primer pair b and c (Supplementary Fig. 1b) .
Generation of a loxP-flanked Ikzf1 allele. The conditional Ikzf1 targeting vector was assembled in the pBV-DTA-pA plasmid containing an gene encoding herpes simplex virus thimidine kinase (for negative selection) as well as a polylinker with appropriate restriction sites for insertion of the following sequences in the 5′-to-3′ direction (Supplementary Fig. 2a) : a 4.8-kb NotISfiI fragment (cloned as long 5′ homology region from the Ikzf1 BAC bMQ-185J16 by recombination-mediated genetic engineering in E. coli), a 5′ loxP site present in the polylinker, a 3.5-kb SalI-AscI fragment (containing the entire Ikzf1 exon 8 including the 3′ untranslated sequence), a 1.3-kb SacII-SalI fragment (containing six copies of the SV40 poly(A) region and the 3′ loxP site), a 2.2-kb ClaI-MluI fragment (containing the Pgk-neo r gene flanked by flippase recognition target sites) and a 1.9-kb XmaI-BsiWI fragment (cloned as short 3′ homology region from the same Ikzf1 BAC by recombination-mediated genetic engineering). DNA (15 µg) linearized by PvuI was transfected by electroporation into cells (1 × 10 7 ) of the hybrid C57BL/6 × 129Sv embryonic stem cell line A9, followed by selection with 250 µg/ml G418. PCR + clones were injected into C57BL/6 blastocysts to generate Ikzf1 fl-neo/+ mice. The Ikzf1 fl allele was obtained by crossing Ikzf1 fl-neo/+ mice with the FLPe line 53 , and both alleles were verified by Southern blot analysis of DNA obtained from tail tissue and digested with KpnI (Supplementary Fig. 2b ). The following primers flanking the 5′ loxP site were used for PCR genotyping of Ikzf1 mutant mice: 5′-TCCTGCTTCCTGTTTCTGCT-3′(a), 5′ -CAGGGGTTGAATGGTGTTCT-3′(b) and 5′ -ACATGGTCCTGCTGGAGTTC-3′ (c). The wild-type Ikzf1 allele was identified as a 558-bp PCR fragment and the Ikzf1 fl allele was identified as a 381-bp PCR fragment with the primer pair a and b (Supplementary Fig. 2c) .
Deletion of the Ikzf1 fl allele (Ikzf1 ∆ ) was detected as a 484-bp PCR fragment with the primer pair a and c (Fig. 1d) .
Antibodies. The following monoclonal antibodies were used for flow cytometry: anti-Aiolos (8B2), anti-B220 (anti-CD45R; RA3-6B2), anti-CD4 (GK1.5), anti-CD19 (1D3), anti-CD38 (90), anti-CD49b (DX5), anti-CD54 (YN1/1.7.4), anti-CD93 (anti-AA4.1; PB493), anti-CD115 (anti-MCSF-R; AFS98), anti-CD127 (anti-IL-7Rα; A7R34), anti-CD135 (anti-Flt3; A2F10.1), anti-IgD (11.26c), anti-IgM (II/41), anti-TCRβ (H57-597), anti-Thy-1.2 (53-2.1) and antibody to human CD2 (RPA-2.10) (all from eBioscience); anti-CD2 (RM2-5), anti-CD3ε (145-2C11), anti-CD8a (53-6.7), anti-CD5 (53-7.3), anti-CD11b (anti-Mac-1; M1/70), anti-CD22 (Cy34.1), anti-CD23 (B3B4), anti-CD25 (anti-IL-2Rα; PC61), anti-CD40 (3/23), anti-CD43 (S7), anti-CD55 (RIKO-5), anti-CD72 (K10.6), anti-CD86 (GL1), anti-CD138 (281-2), anti-CD352 (13G3), anti-Ly5.1 (A20), anti-Ly6D (49H4), antibody to Erk1/2 phosphorylated at Thr202 and Tyr204 (20A) and anti-Ter-119 (TER119) (all from BD Bioscience); anti-BP-1 (6C3), anti-CD11c (HL3; N418), anti-CD21-CD35 (7G6), anti-CD28 (37.51), anti-CD117 (anti-c-Kit; 2B8), anti-CD179a (anti-VpreB; R3), anti-Gr-1 (RB6-8C5), anti-IgMb (AF6-78), anti-Ikaros (2A9), anti-NK1.1 (PK136), anti-Ly5.2 (104), anti-Ly6C (6C3) and anti-Sca-1 (anti-Ly6A; D7) (all from Biolegend); antibody to Akt phosphorylated at Ser473 (D9E; Cell Signaling Technology); anti-CD16/32 (2.4G2), anti-CD24 (anti-HSA; M1/69), anti-CD44 (IM781), anti-CD179b (anti-λ5; LM34), anti-F4/80 (CI:A3-1) and antibody to major histocompatibility complex class II (M5-114) (all produced in-house).
The following antibodies were used for immunoblot analysis: mouse monoclonal antibody (mAb) to Ikaros (4E9; K. Georgopoulos), mouse mAb to TBP (3TF1-3G3; Active Motif). The following antibodies were used for cell stimulation or intracellular staining: Armenian hamster IgG2 mAb to CD79b (HM79; from Hajime Karasuyama), Armenian hamster IgG2 mAb to TCRγδ (GL-3), anti-Ikaros (2A9, Biolegend; Supplementary Fig. 1f,g ) and rabbit polyclonal antibody to Ikaros (5443; Cell Signaling Technology; Supplementary Fig. 8d,e) .
Flow cytometry and definition of hematopoietic cell types. All cell-type and expression analyses used with age-matched experimental and control mice and were repeated at least three times in independent experiments. Prism software In vitro culture of lymphoid progenitor cells. Cd79a-Cre Ikzf1 fl/− , Cd79a-Cre Ikzf1 fl/+ and Rag2 −/− pro-B cells were cultured on OP9 stromal cells in pro-B cell medium (IMDM containing IL-7) as described 55 . EBF1-deficient progenitors were generated by in vitro culture of sorted Lin − bone marrow cells from Ebf1 −/− mice in IMDM containing IL-7 and the cytokines Flt3L and SCF as described 56 .
npg Cell-cycle analysis. At 40 min after intraperitoneal injection of BrdU (5-bromodeoxyuridine; 1 mg per mouse), single-cell suspensions were prepared from bone marrow and were stained for cell surface proteins with the following antibodies (identified above): anti-CD19, anti-IgM, anti-IgD, anti-CD2 and anti-c-Kit. Cultured pro-B cells were treated for 30 or 45 min with 10 µM BrdU. BrdU was stainied with an APC BrdU Flow Kit (557892) according to the manufacturer's protocol (BD Pharmingen). Shortly thereafter, surface-stained cells were fixed and permeabilized and then treated with DNase I. Incorporated BrdU was stained with anti-BrdU and total DNA was stained with 7-amino-actinomycin D. Single cells were analyzed with a Fortessa flow cytometer and data were evaluated with FlowJo software.
Calcium fluorimetry. Pro-B cells (1 × 10 6 ) were loaded with the calciumsensor dye eFluor 514 (eBioscience) at a final concentration of 1 µM in 1 ml of pro-B cell medium (IMDM containing IL-7). After incubation for 30 min at 37 °C, the cells were washed and the fluorescence emission at 530/30 nm (excitation at 488 nm) was measured in live cells on a Fortessa flow cytometer. The acquisition of data was initiated 60 s before the addition of mAbs at a concentration of 10 µg/ml. Data were collected for 300 s and were analyzed with FlowJo software. The increase in fluorescence (∆F / F 0 ) was plotted against time after stimulation, where 'F 0 ' indicates the average fluorescence between 0s and 30 s before the addition of antibody and '∆F' indicates the measured fluorescence at time 't' minus F 0 .
Transwell migration. Pro-B cells were washed and then were resuspended at a density of 3 × 10 6 to 5 × 10 6 cells per ml in IMDM supplemented with 0.25% heat-inactivated FCS, 1 mM glutamine, 50 µM β-mercaptoethanol and 1% conditioned supernatant of J558L mouse plasmacytoma cells that produce recombinant IL-7. The pro-B cell suspension (100 µl) was placed in the upper compartment and pro-B cell medium (IMDM containing IL-7) (600 µl) containing 400 ng/ml CXCL12 (SDF-1α; Sigma) in the lower compartment of a Transwell chamber (pore size, 5 µm; Corning). Pro-B cells that had migrated into the lower chamber were measured after 2 h with a Casy cell counter, and their frequency among total cells was calculated.
Adhesion assay. The adhesion of pro-B cells to VCAM1-coated chamber slide was analyzed as follows. Eight-well chamber slides (Nunc) were coated for 1.5 h at 22 °C with a fusion of recombinant mouse VCAM-1 and crystallizable fragment (Fc) (25 mg/ml; R&D Systems) and then washed three times with PBS, followed by the addition of 1 × 10 5 pro-B cells in 0.2 ml pro-B cell medium (IMDM containing IL-7) supplemented with 100 ng/ml CXCL12 (SDF-1α; Sigma). After incubation for 6 h at 37 °C, the chambers were removed and the slides were washed with pre-warmed pro-B cell medium and then with PBS, followed by fixation for 15 min at 22 °C with 4% paraformaldehyde in PBS. The slides were washed three times with PBS, then were stained for 30 min with 0.1% Crystal Violet and then were washed with distilled water and dried. Cells that were attached to the glass slides were manually counted as viewed with a microscope. For each genotype, the cells from eight wells (0.7 cm 2 ) were counted to determine the cells per cm 2 .
Ikzf1-specific shRNA-mediated knockdown. Two Ikzf1-specific shRNA (Ik2709 and Ik4056) and control shRNA (Ren713) were cloned into the TRMPVIR vector 29 containing the optimized miR-E backbone 30 . The following 22-nt shRNA 'guide sequences' were used for cloning: 5′-TTTGTGGAATAACAGGTCCTGG-3′ (Ik2709); 5′-TTAATCTCT GAATA CCACTGGT-3′ (Ik4056) and 5′-TAGATAAGCATTATAATTCCTA-3′ (Ren713). Retroviruses was produced by transfection of 20 µg of the retroviral vector together with 10 µg of the helper vector into Plat-E packaging cells by standard calcium phosphate transfection in the presence of 25 µM chloroquine. At 24 h after transfection, the high-titer viral supernatant was collected in progenitor cell medium (IMDM containing IL-7, Flt3L and SCF) 56 , then was passed through a 0.45-µm filter and supplemented with 4 µg/ml of polybrene. Cells in six-well plates were infected by being spun for 15 min. Each well contained 1 × 10 6 Ebf1 −/− progenitor cells with OP9 cells in progenitor cell medium containing 1 ml of freshly collected viral supernatant. The infection was repeated five times every 5-8 h. At 48 h after the final infection, the cells were treated with doxycycline (1 µg/ml) to induce shRNA expression.
After 4 d of induction, Venus hi dsRed hi CD11b − progenitor cells were sorted by flow cytometry to select for high shRNA expression and against the presence of CD11b + myeloid cells. The sorted cells were subjected to RNA preparation and cDNA synthesis, followed by Illumina deep sequencing. For analysis of Ikaros protein expression, cells were treated with doxycycline for 3 d before intracellular flow cytometry staining and immunoblot analysis of lysates prepared from dsRed hi cells sorted by flow cytometry.
ChIP-Seq analysis of histone modifications and binding of IRF4 and Mi-2. Populations of pro-B cells from the bone marrow of Rag2 −/− mice were expanded in vitro for 4-5 d on OP9 stromal cells in the presence of IL-7 before ChIP with goat polyconal antibody to IRF4 (sc-6059; Santa Cruz) as described 57 . For chromatin profiling, pro-B cells from the bone marrow of Cd79a-Cre Ikzf1 fl/− Rag2 −/− and Cd79a-Cre Ikzf1 fl/+ Rag2 −/− mice were cultured short-term as described above, and samples were enriched for live pro-B cells by density-gradient purification with Lympholyte M (Cedarlane Laboratories) before ChIP analysis 57 with antibodies specific for histone modification; the following rabbit polyclonal antibodies to modifications of histone tails were used for ChIP analysis: anti-H3K4me3 (pAb-003-050) from Diagenode and anti-H3K9ac (07-352) from Millipore. ChIP efficiency was quantified by real-time PCR analysis with SYBR Green as described 56 . The DNA precipitated by ChIP was subjected to Illumina deep sequencing.
For analysis of the binding of Mi-2β (CHD4), pro-B cells from the bone marrow of Cd79a-Cre Ikzf1 fl/− and Cd79a-Cre Ikzf1 fl/+ mice were cultured as described above. Cells were then fixed for 45 min at 22 °C with 2 mM disuccinimidyl glutarate (Sigma), then were fixed for 10 min with 1% formaldehyde. The fixed cells were subjected to nuclei preparation and lysis, and chromatin was sheared with a Biorupter sonicator (Diagenode) in the presence of 0.1% SDS. Chromatin was immunoprecipitated with mouse mAb to Mi-2β (3F2/4; Abcam) as described above (further information, Supplementary Table 2 Rosa26 BirA/BirA mice were enriched for DP thymocytes by immunomagnetic selection of CD8 + T cells, which resulted in 85% enrichment for DP thymocytes. Chromatin from ~1 × 10 8 pro-B cells or DP thymocytes was prepared with lysis buffer containing 0.25% SDS (for Ikaros) or 1% SDS (for PU.1) before precipitation of chromatin with streptavidin (Bio-ChIP) as described 58 . The precipitated genomic DNA was quantified by real-time PCR, and about 5 ng of ChIP-precipitated DNA was subjected to Illumina deep sequencing (further information, Supplementary Table 2 Fig. 4a) , as well as wild-type pre-B cells (c-Kit − CD19 + CD2 + IgM − IgD − ) containing >90% small and <10% large pre-B cells.
RNA from those cells (cultured in vitro and sorted ex vivo) was isolated with an RNeasy Plus Mini Kit (Qiagen), and mRNA was obtained by two rounds of poly(A) selection with a Dynabeads mRNA purification kit (Invitrogen), followed by fragmentation by heating at 94 °C for 3 min (in fragmentation buffer). The fragmented mRNA was used as template for first-strand cDNA synthesis with random hexamers and a Superscript VILO cDNA Synthesis kit (Invitrogen). The second-strand cDNA was synthesized with 100 mM dATP, dCTP, dGTP and dUTP in the presence of RNase H, npg
